27.06.2011 • News • Clariant • Hans-Joachim Müller • People

Clariant Appoints Hans-Joachim Müller Member of the Executive Committee

Clariant said it has appointed Dr. Hans-Joachim Müller member of the Executive Committee. He will join the company on July 1.

Müller joins Clariant from Süd-Chemie, where he was a member of the managing board. Before he was head of the global Business Unit Catalytic Technologies at Süd-Chemie, developing this business into a global market leading position. He holds a PhD in chemistry from the Ludwig-Maximilian-University in Munich, Germany.

Clariant's CEO Hariolf Kottmann commented: "I am pleased that Hans-Joachim Müller has accepted the offer to join the Executive Committee of Clariant. With his broad leadership experience in the chemicals industry and his deep understanding of the Süd-Chemie businesses he will guarantee for continuity and contribute to the successful execution of our profitable growth strategy."

Müller will be responsible for the two business units Catalysis & Energy and Functional Materials.

 

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Top-Feature

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.